Mechanisms of Anemia in CKD

被引：726

作者：

Babitt, Jodie L. ^{[1
]}

Lin, Herbert Y. ^{[1
]}

机构：

[1] Harvard Univ, Program Anemia Signaling Res, Massachusetts Gen Hosp, Nephrol Div,Program Membrane Biol,Ctr Syst Biol,M, Boston, MA 02114 USA

来源：

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2012年 / 23卷 / 10期

基金：

美国国家卫生研究院;

关键词：

HEMODIALYSIS-PATIENTS; HUMAN-ERYTHROPOIETIN; KIDNEY-DISEASE; EPOETIN-ALPHA; RENAL-FAILURE; HEPCIDIN; SERUM; PEPTIDE; INFLAMMATION; FERROPORTIN;

D O I：

10.1681/ASN.2011111078

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Anemia is a common feature of CKD associated with poor outcomes. The current management of patients with anemia in CKD is controversial, with recent clinical trials demonstrating increased morbidity and mortality related to erythropoiesis stimulating agents. Here, we examine recent insights into the molecular mechanisms underlying anemia of CKD. These insights hold promise for the development of new diagnostic tests and therapies that directly target the pathophysiologic processes underlying this form of anemia.

引用

页码：1631 / 1634

页数：4

共 41 条

[1] Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease [J].

Ashby, Damien R. ;

Gale, Daniel P. ;

Busbridge, Mark ;

Murphy, Kevin G. ;

Duncan, Neill D. ;

Cairns, Tom D. ;

Taube, David H. ;

Bloom, Stephen R. ;

Tam, Frederick W. K. ;

Chapman, Richard S. ;

Maxwell, Patrick H. ;

Choi, Peter .

KIDNEY INTERNATIONAL, 2009, 75 (09) :976-981

[2] Molecular Mechanisms of Hepcidin Regulation: Implications for the Anemia of CKD [J].

Babitt, Jodie L. ;

Lin, Herbert Y. .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (04) :726-741

[3] Intersecting Guidelines: Administering Erythropoiesis-Stimulating Agents to Chronic Kidney Disease Patients with Cancer [J].

Bennett, Charles L. ;

Becker, Pamela S. ;

Kraut, Eric H. ;

Samaras, Athena T. ;

West, Dennis P. .

SEMINARS IN DIALYSIS, 2009, 22 (01) :1-4

[4] The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].

Besarab, A ;

Bolton, WK ;

Browne, JK ;

Egrie, JC ;

Nissenson, AR ;

Okamoto, DM ;

Schwab, SJ ;

Goodkin, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590

[5]

Besarab A., 2007, DIS KIDNEY URINARY T, V8th, P2406

[6]

Bright R, 1836, GUYS HOSP REP, V1, P338

[7] IMMUNOREACTIVE ERYTHROPOIETIN IN SERUM .1. EVIDENCE FOR THE VALIDITY OF THE ASSAY-METHOD AND THE PHYSIOLOGICAL RELEVANCE OF ESTIMATES [J].

COTES, PM .

BRITISH JOURNAL OF HAEMATOLOGY, 1982, 50 (03) :427-438

[8] AN IMMUNOLOGICAL CROSS-REACTANT OF ERYTHROPOIETIN IN SERUM WHICH MAY INVALIDATE EPO RADIOIMMUNOASSAY [J].

COTES, PM ;

TAM, RC ;

REED, P ;

HELLEBOSTAD, M .

BRITISH JOURNAL OF HAEMATOLOGY, 1989, 73 (02) :265-268

[9] HUMORAL REGULATION OF RED CELL PRODUCTION [J].

ERSLEV, A .

BLOOD, 1953, 8 (04) :349-357

[10] ERYTHROPOIESIS IN PATIENTS WITH RENAL FAILURE UNDERGOING CHRONIC DIALYSIS [J].

ESCHBACH, JW ;

FUNK, D ;

ADAMSON, J ;

KUHN, I ;

SCRIBNER, BH ;

FINCH, CA .

NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (12) :653-&

← 1 2 3 4 5 →